Is PRAX or VERA more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Vera Therapeutics N/A -74.86% -60.18%

Does the media prefer PRAX or VERA?

In the previous week, Praxis Precision Medicines had 16 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Praxis Precision Medicines and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Praxis Precision Medicines' score of -0.14 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or CYTK?

In the previous week, Cytokinetics had 8 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Cytokinetics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Cytokinetics' score of 0.21 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KRYS or VERA?

In the previous week, Krystal Biotech had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Krystal Biotech and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Krystal Biotech's score of 0.45 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NUVL or VERA?

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is NUVL or VERA more profitable?

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Vera Therapeutics N/A -74.86% -60.18%

Does the media prefer NUVL or VERA?

In the previous week, Nuvalent had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 11 mentions for Nuvalent and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Nuvalent's score of 0.15 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or IBRX?

In the previous week, ImmunityBio had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat ImmunityBio's score of 0.45 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Vera Therapeutics (VERA) Competitors

$31.27 +0.01 (+0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$31.70 +0.43 (+1.36%)

As of 07:23 PM Eastern

Compare

VERA vs. PRAX, CYTK, KRYS, NUVL, and IBRX

Should you buy Vera Therapeutics stock or one of its competitors? MarketBeat compares Vera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vera Therapeutics include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Vera Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Praxis Precision Medicines' return on equity of -43.02% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Vera Therapeutics	N/A	-74.86%	-60.18%

In the previous week, Praxis Precision Medicines had 16 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Praxis Precision Medicines and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Praxis Precision Medicines' score of -0.14 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	909.54	-$303.27M	-$13.37	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Praxis Precision Medicines presently has a consensus target price of $572.72, indicating a potential upside of 105.33%. Vera Therapeutics has a consensus target price of $78.00, indicating a potential upside of 149.44%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Praxis Precision Medicines beats Vera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Cytokinetics?

Vera Therapeutics (NASDAQ:VERA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Vera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Cytokinetics	$88.04M	99.94	-$784.96M	-$6.84	N/A

Vera Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Vera Therapeutics presently has a consensus price target of $78.00, suggesting a potential upside of 149.44%. Cytokinetics has a consensus price target of $99.30, suggesting a potential upside of 40.43%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 8 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Cytokinetics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Cytokinetics' score of 0.21 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vera Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 7.39%. Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 149.44%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Krystal Biotech had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Krystal Biotech and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Krystal Biotech's score of 0.45 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 53.92% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Vera Therapeutics	N/A	-74.86%	-60.18%

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Summary

Krystal Biotech beats Vera Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Nuvalent had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 11 mentions for Nuvalent and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat Nuvalent's score of 0.15 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Vera Therapeutics	N/A	-74.86%	-60.18%

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Nuvalent presently has a consensus price target of $141.24, suggesting a potential upside of 56.61%. Vera Therapeutics has a consensus price target of $78.00, suggesting a potential upside of 149.44%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Summary

Nuvalent and Vera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to ImmunityBio?

Vera Therapeutics (NASDAQ:VERA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vera Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
ImmunityBio	$113.29M	66.38	-$351.40M	-$0.85	N/A

Vera Therapeutics presently has a consensus price target of $78.00, suggesting a potential upside of 149.44%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 97.77%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vera Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Vera Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

In the previous week, ImmunityBio had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.08 beat ImmunityBio's score of 0.45 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
ImmunityBio	-606.15%	N/A	-59.53%

Summary

Vera Therapeutics beats ImmunityBio on 9 of the 15 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.24B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-5.64	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.69	6.63	9.84	6.72
Net Income	-$299.61M	$24.20M	$3.57B	$337.19M
7 Day Performance	-8.75%	-3.24%	-1.16%	0.48%
1 Month Performance	-11.16%	0.53%	3.85%	5.07%
1 Year Performance	1.16%	47.24%	27.40%	34.25%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.3442 of 5 stars	$31.27 +0.0%	$78.00 +149.4%	-1.5%	$2.24B	N/A	N/A	40	News Coverage Positive News Analyst Forecast
PRAX Praxis Precision Medicines	3.134 of 5 stars	$335.16 -4.2%	$592.67 +76.8%	+548.1%	$9.76B	$8.55M	N/A	110	Trending News Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.7781 of 5 stars	$73.68 -4.0%	$99.30 +34.8%	+127.2%	$9.55B	$88.04M	N/A	250	Positive News Insider Trade
KRYS Krystal Biotech	3.2722 of 5 stars	$298.10 -3.5%	$324.11 +8.7%	+133.9%	$9.11B	$417.30M	39.85	210	Analyst Forecast
NUVL Nuvalent	3.439 of 5 stars	$93.01 -15.7%	$140.29 +50.8%	+18.4%	$8.72B	N/A	N/A	40	News Coverage Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Vera Therapeutics compare to Praxis Precision Medicines?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Summary

How does Vera Therapeutics compare to Nuvalent?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Vera Therapeutics compare to Praxis Precision Medicines?

Do insiders and institutionals hold more shares of PRAX or VERA?

Which has more risk & volatility, PRAX or VERA?

Is PRAX or VERA more profitable?

Does the media prefer PRAX or VERA?

Which has higher earnings and valuation, PRAX or VERA?

Do analysts rate PRAX or VERA?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Which has stronger valuation & earnings, VERA or CYTK?

Which has more risk & volatility, VERA or CYTK?

Do analysts rate VERA or CYTK?

Do institutionals & insiders hold more shares of VERA or CYTK?

Is VERA or CYTK more profitable?

Does the media refer more to VERA or CYTK?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Do insiders & institutionals hold more shares of KRYS or VERA?

Which has more risk & volatility, KRYS or VERA?

Do analysts recommend KRYS or VERA?

Does the media prefer KRYS or VERA?

Is KRYS or VERA more profitable?

Which has stronger earnings & valuation, KRYS or VERA?

Summary

How does Vera Therapeutics compare to Nuvalent?

Does the media prefer NUVL or VERA?

Is NUVL or VERA more profitable?

Which has higher valuation and earnings, NUVL or VERA?

Do analysts recommend NUVL or VERA?

Do institutionals & insiders hold more shares of NUVL or VERA?

Which has more volatility and risk, NUVL or VERA?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Do institutionals & insiders have more ownership in VERA or IBRX?

Which has better earnings and valuation, VERA or IBRX?

Do analysts rate VERA or IBRX?

Which has more risk & volatility, VERA or IBRX?

Does the media refer more to VERA or IBRX?

Is VERA or IBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools